enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q2 2025 vs. Q1 2025
How the institutions holding enGene Therapeutics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 31 | 36 | +5 |
| Shares | 40.9M | 40.4M | −530.9K (−1.3%) |
| Value | $183.4M | $147.1M | −$36.3M (−19.8%) |
New holders (8)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Affinity Asset Advisors, LLC | 77,000 | $280.3K | 0.04% |
| Citadel Advisors LLC | 23,043 | $83.9K | 0.00% |
| Millennium Management LLC | 13,030 | $47.4K | 0.00% |
| Renaissance Technologies LLC | 11,400 | $41.5K | 0.00% |
| Paloma Partners Management Co | 10,319 | $37.6K | 0.01% |
| Wolverine Asset Management LLC | 6,361 | $23.2K | 0.00% |
| Raymond James Financial Inc | 2,068 | $7.53K | 0.00% |
| NBC Securities, Inc. | 380 | $1.00K | 0.00% |
Sold out (3)
Institutions that held enGene Therapeutics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Two Sigma Investments, LP | 15,832 | $70.9K |
| Sectoral Asset Management Inc | 11,700 | $52.4K |
| UBS Group AG | 1,200 | $5.38K |